Provera Dose for Menorrhagia
For abnormal uterine bleeding (menorrhagia), medroxyprogesterone acetate (Provera) should be dosed at 5-10 mg daily for 5-10 days, with 10 mg daily for 10 days being the optimal regimen for adequate endometrial transformation and bleeding control. 1
Dosing Algorithm
The FDA-approved dosing for abnormal uterine bleeding follows this structure 1:
- Standard dose: 5-10 mg daily for 5-10 days
- Optimal dose: 10 mg daily for 10 days (produces optimal secretory transformation of adequately primed endometrium)
- Timing: Can be started on calculated day 16 or 21 of menstrual cycle, or at any time in cases of secondary amenorrhea
- Expected response: Progestin withdrawal bleeding typically occurs within 3-7 days after discontinuing therapy
For Recurrent Episodes
Women with recurrent abnormal uterine bleeding may benefit from planned menstrual cycling: 5-10 mg daily for 12-14 consecutive days per month 1. This can be initiated either on day 1 or day 16 of the cycle.
Evidence-Based Considerations
The 10-day protocol is superior to shorter durations. Recent evidence demonstrates that a 10-day cyclic regimen (days 16-25) more effectively regulates menstrual cycles and stops abnormal bleeding compared to a 15-day protocol, with 3 cycles typically sufficient to achieve bleeding cessation 2.
Acute Heavy Bleeding
For acute, severe menorrhagia requiring immediate intervention:
- High-dose oral regimen: 20 mg three times daily for 3 days, then reduce to 20 mg daily for 3 weeks 3
- Combination approach: Depot medroxyprogesterone acetate 150 mg IM injection plus oral medroxyprogesterone 20 mg every 8 hours for 3 days (9 doses total) - this achieves bleeding cessation in 100% of patients within 5 days, with mean cessation at 2.6 days 4
- Adolescent protocol: 60-120 mg total dose on day 1, then 20 mg daily for 10 days - achieves bleeding cessation in 25% within 24 hours and 75% within 4 days 5
Important Clinical Caveats
Start at the lowest effective dose and reassess regularly (every 3-6 months) to determine if continued treatment is necessary 1. The lowest effective dose has not been definitively established by FDA standards.
Rule out underlying pathology first. Before initiating treatment, exclude pregnancy, sexually transmitted infections, thyroid disorders, coagulopathies, and structural uterine pathology (polyps, fibroids, malignancy) 6, 7. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken for undiagnosed persistent or recurrent bleeding 1.
Comparative Effectiveness
While medroxyprogesterone is effective, the levonorgestrel-releasing intrauterine system (LNG-IUS) demonstrates superior efficacy for long-term menorrhagia management, with greater reduction in blood loss and higher hemoglobin levels 8, 9. However, oral medroxyprogesterone remains an appropriate first-line option, particularly when IUD placement is not feasible or desired.
Antifibrinolytics (tranexamic acid) and NSAIDs are alternative first-line options that may be considered based on patient preference, contraindications, and treatment goals 9.
Side Effects to Monitor
Common side effects include 1:
- Breakthrough bleeding or spotting (especially in first months)
- Breast tenderness
- Headaches
- Nausea and bloating
- Weight gain
- Mood changes
Serious warning signs requiring immediate evaluation include new breast lumps, unusual vaginal bleeding patterns, severe headaches, chest pain, or leg pain with swelling 1.